



acadia  
medical affairs

Acadia Pharmaceuticals Inc. is providing this letter in response to your unsolicited request for medical information. It is for scientific-exchange and individual educational purposes only, and should not be copied or distributed. Information included in this letter may not be consistent with the US FDA-approved Prescribing Information for NUPLAZID® (pimavanserin) or may be related to unapproved uses of NUPLAZID. This letter is not intended to advocate any unapproved or approved use, indication, dosage, or other treatment-related decision. Acadia strives to provide current, accurate, and fair-balanced information in compliance with current industry information dissemination guidelines.

For further information regarding Indication, **Boxed WARNING** and other Important Safety Information for NUPLAZID, please click here: [Prescribing Information](#).

## NUPLAZID<sup>®</sup> (pimavanserin) Discontinuation

This letter is being provided based on your specific request for information on how to discontinue treatment with pimavanserin.

There was no protocol for participants discontinuing pimavanserin in the Acadia-sponsored clinical trial program in Parkinson's disease psychosis.<sup>1-4</sup> Acadia Pharmaceuticals Inc. does not have any additional information regarding how to discontinue pimavanserin.

The mean plasma half-lives for pimavanserin and the active metabolite (N-desmethylated metabolite) are approximately 57 hours and 200 hours, respectively.<sup>5</sup> Physicians should exercise clinical judgment when discontinuing this product.

### References

---

1. Acadia Pharmaceuticals Inc. Data on file. ACP-103-006 Protocol. 2003.
2. Acadia Pharmaceuticals Inc. Data on file. ACP-103-012 Protocol. 2007.
3. Acadia Pharmaceuticals Inc. Data on file. ACP-103-014 Protocol. 2008.
4. Acadia Pharmaceuticals Inc. Data on file. ACP-103-020 Protocol. 2010.
5. NUPLAZID<sup>®</sup> (pimavanserin) [package insert]. San Diego, CA. Acadia Pharmaceuticals Inc. [[Link](#)].